학술논문

The Global Phosphorylation Landscape of SARS-CoV-2 Infection.
Document Type
article
Source
Cell. 182(3)
Subject
Caco-2 Cells
Vero Cells
Animals
Humans
Pneumonia
Viral
Coronavirus Infections
Peptidyl-Dipeptidase A
Casein Kinase II
Cyclin-Dependent Kinases
p38 Mitogen-Activated Protein Kinases
Receptor Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Protein Kinase Inhibitors
Antiviral Agents
Drug Evaluation
Preclinical
Proteomics
Phosphorylation
Host-Pathogen Interactions
Phosphatidylinositol 3-Kinases
HEK293 Cells
Pandemics
Spike Glycoprotein
Coronavirus
A549 Cells
Betacoronavirus
Phosphoinositide-3 Kinase Inhibitors
Chlorocebus aethiops
COVID-19
Angiotensin-Converting Enzyme 2
SARS-CoV-2
AXL
CDK
MAPK
PIKFYVE
antiviral
casein kinase II
mass spectrometry
p38
phosphoproteomics
Infectious Diseases
Prevention
Biodefense
Emerging Infectious Diseases
Vaccine Related
Lung
Infection
Developmental Biology
Biological Sciences
Medical and Health Sciences
Language
Abstract
The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed hundreds of thousands of people worldwide, highlighting an urgent need to develop antiviral therapies. Here we present a quantitative mass spectrometry-based phosphoproteomics survey of SARS-CoV-2 infection in Vero E6 cells, revealing dramatic rewiring of phosphorylation on host and viral proteins. SARS-CoV-2 infection promoted casein kinase II (CK2) and p38 MAPK activation, production of diverse cytokines, and shutdown of mitotic kinases, resulting in cell cycle arrest. Infection also stimulated a marked induction of CK2-containing filopodial protrusions possessing budding viral particles. Eighty-seven drugs and compounds were identified by mapping global phosphorylation profiles to dysregulated kinases and pathways. We found pharmacologic inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.